The arterial cannula market size is estimated to be USD 19.89 million in 2022 and is expected to witness a CAGR of 7.85% during the forecast period 2023-2033. Rising incidence of chronic diseases, higher health care costs, improvements in developing-nation healthcare facilities, and sedentary lifestyles of the general population that cause obesity and cardiac diseases are some of the factors contributing to the market growth. Furthermore, increase in incidence of cardiovascular diseases and growing geriatric population are other factors supporting the market growth. However, increasing equipment costs and a shortage of skilled physicians is expected to hinder the growth.

Increase in incidence of cardiovascular diseases is projected to drive the market growth during the forecast period. More than 90% of patients with type 2 diabetes (T2D) are at high risk of developing fatal heart disease or stroke within 10 years, according to a study published in the European Publication of Preventive Cardiology, the official journal of the European Association of Preventive Cardiology. Therefore, a rise in risk factors including diabetes and hypertension is probably going to result in an increase in the prevalence of cardiovascular diseases (CVDs), which would increase the demand for the product over the projected period.

Growing geriatric population is expected to propel the market growth during the projected period. The sector is expanding in particular geriatric population that is more susceptible to developing chronic diseases. The number of Americans 65 and over increased from 40.3 million in 2010 to 54.1 million in July 2019, according to the U.S. Census Bureau. Large geriatric populations in Asian nations like Japan, China, and India create significant growth potential for the sector in this area.

Segmentation

By Size

The market is categorized into14-16 Fr, 17-19 Fr, 20-22 Fr, 23-25 Fr, 26-28 Fr, 29-31 Fr, 32-34 Fr, 35-36 Fr. In 2022, the 20-22 Fr segment accounted for the highest revenue share due to the rise in the use of cannulas of this size when performing ECMO operations. As more patients needed ECMO during the pandemic, particularly those who were virus-infected, the need for these cannulas unexpectedly increased. Healthcare providers should usually follow the general rule of choosing the smallest size that still allows for effective drainage when choosing the size. In terms of revenue share for the entire industry in 2022, the 23–25 Fr size segment placed second. The widespread use of these cannulas in cardiopulmonary bypass procedures was the cause of this. On the other hand, it is anticipated that the 35-36 Fr size segment will increase at the quickest rate throughout the projected period.

By Application

The market is categorized into extracorporeal membrane oxygenation, cardiopulmonary bypass surgery, and others. In the global market, the extracorporeal membrane oxygenation segment accounted for the largest revenue share in 2022 owing to higher prevalence of respiratory and heart disorders. In 2022, the American Lung Association projects that almost 37 million Americans have a chronic lung disease, such as COPD, asthma, chronic bronchitis, or emphysema. COPD, an obstructive lung condition that over time makes breathing more difficult, has been identified as affecting around 15 million adult Americans. This shows that the primary reason of the ECMO segment’s dominance is the rising prevalence of respiratory diseases, which could ultimately lead to lung failure. Contrarily, the cardiopulmonary bypass surgery market is anticipated to develop at the fastest rate over the forecast period. This is due to heart conditions that require for cardiopulmonary bypass surgery are becoming more common.

By End User

The market is segmented into ambulatory surgical centres, hospitals, and others. In 2022, the hospitals segment accounted for the largest revenue share owing to high number of procedures carried out in these locations. Additionally, the accessibility of all varieties of trained personnel and surgical equipment is anticipated to fuel the segment’s expansion. Over the projected period, the segment’s growth is anticipated to be fueled by an increase in admissions due to a rise in chronic disorders. The ASCs segment is also anticipated to experience considerable increase over the course of the forecast period due to people’s growing preference for having surgical procedures done in ASCs. ASCs are becoming more popular for a variety of reasons, including decreased overall costs and shorter patient hospital stays post-surgery.

Regional Markets

In 2022, North America region accounted for the highest revenue in the arterial cannula market and is expected to maintain its dominance during the forecast period. This is attributed to the region’s high prevalence of chronic kidney disease and growing cardiac surgery volume. The CDC estimates that there were 7,433 dialysis facilities in the US in 2018, with 518,749 individuals receiving treatment. In the United States, there were generally about 70 patients each facility. Additionally, the prevalence of lung-damaging respiratory conditions like COPD and asthma is very high in this area. In terms of revenue, Europe had the second-largest share. The region’s growth is fueled by elements such as the increasing geriatric population, particularly in nations including Italy, expanding government efforts, and advantageous reimbursement scenarios.

Competitor Insights

Some of the key players operating in the arterial cannula market are BD, Edward Lifesciences, Getinge AB, LivaNova plc, Fresenius Medical Care, Andocor, Freelife Medical GmbH, Surgical Holdings, Medtronic, plc, Nipro Corp., and Kangxin Medical.

To achieve a competitive edge, these companies are implementing a variety of growth strategies. Strategic partnerships, alliances, and agreements with different businesses and research institutions are seen to be the main strategies used by companies in this sector.

• For instance, LivaNova Plc. obtained a CE mark in April 2020 for its Bi-Flow Extracorporeal Membrane Oxygenation (ECMO) cannula for ECMO operations, which allow for the application of femoral artery cannulation.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including size, application, and end user from 2023 to 2033.

Report Scope:

Segmentation Arterial Cannula Market Report 2022 – 2033

Size (Revenue, USD Million), 2022 – 2033

• 14-16 Fr
• 17-19 Fr
• 20-22 Fr
• 23-25 Fr
• 26-28 Fr
• 29-31 Fr
• 32-34 Fr
• 35-36 Fr

Application (Revenue, USD Million), 2022 – 2033

• Extracorporeal Membrane Oxygenation
• Cardiopulmonary Bypass Surgery
• Others

End user (Revenue, USD Million), 2022 – 2033

• Ambulatory Surgical Centres
• Hospitals
• Others

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA